Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Abstract Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease mechanisms and alterations of biomarkers during the development of AD. Using cross‐sectional data from 377 participants in the BioFINDER study, we examined seven cerebrospinal fluid (CSF) and...
Saved in:
| Main Authors: | Sebastian Palmqvist, Philip S Insel, Erik Stomrud, Shorena Janelidze, Henrik Zetterberg, Britta Brix, Udo Eichenlaub, Jeffrey L Dage, Xiyun Chai, Kaj Blennow, Niklas Mattsson, Oskar Hansson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2019-11-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201911170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The genetic regulation of protein expression in cerebrospinal fluid
by: Oskar Hansson, et al.
Published: (2022-12-01) -
18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
by: Niklas Mattsson, et al.
Published: (2017-07-01) -
Alcohol consumption and cerebrospinal fluid biomarkers for preclinical alzheimer’s disease in a population-based sample of 70-year-olds
by: Silke Kern, et al.
Published: (2025-07-01) -
Olfactory dysfunction and amyloid-positivity in Parkinson’s disease—longitudinal analysis of cognitive decline and cerebrospinal fluid markers
by: Victoria Larsson, et al.
Published: (2025-01-01) -
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
by: Gemma Salvadó, et al.
Published: (2023-03-01)